News

Recordati has acquired worldwide rights over Novartis‘ investigational therapy osilodrostat (LCI699), being developed for the treatment of endogenous Cushing’s disease. The agreement also covers Signifor (pasireotide), an approved treatment for adults with Cushing’s disease who failed surgery or who were not eligible for surgery,…